3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
7
Terminated
5
Recruiting
4
Active not recruiting
2
Withdrawn
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Lymphoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Leukemia, Myeloid, Acute
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Central Nervous System Neoplasms
2
Waldenstrom Macroglobulinemia
1
Sezary Syndrome
1
Sarcoma
1
Rhabdoid Tumor
1
Retinoblastoma
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Mycosis Fungoides
1
Medulloblastoma
1
Lymphoproliferative Disorders
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Myelomonocytic, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Monocytic, Acute
1
Leukemia, Megakaryoblastic, Acute
1
Leukemia, Erythroblastic, Acute
1
Interventions
fludarabine
6
Cyclophosphamide
5
fludarabine phosphate
4
Whole-Body Irradiation
4
itacitinib
3
angiotensin I (1-7)
3
pembrolizumab
2
Tacrolimus
2
Olanzapine
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Ipilimumab
2
INCB039110
2
CTLA-4 Antigen
2
Busulfan
2
Brentuximab Vedotin
2
Bendamustine Hydrochloride
2
AP 1903 reagent
2
tazemetostat
1
tafasitamab
1
ruxolitinib
1
pomalidomide
1
ofatumumab
1
merphos
1
lopinavir-ritonavir drug combination
1
ivosidenib
1
ibrutinib
1
fedratinib
1
enasidenib
1
daratumumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Hematologic Neoplasms
×
Thiotepa
×
Clear all
NCT04282174
2022-09-27
2019-KOE-001
Baptist Health South Florida
Phase 2
Withdrawn